EZH2 Inhibitor Enhances the STING Agonist‒Induced Antitumor Immunity in Melanoma
- 1 April 2022
- journal article
- research article
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (4) , 1158-1170.e8
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81972562, 82073011)
- Natural Science Foundation of Beijing Municipality (7202024)
- Beijing Municipal Excellent Talents Foundation (2016000021223ZK18)
This publication has 50 references indexed in Scilit:
- Structure of Human cGAS Reveals a Conserved Family of Second-Messenger Enzymes in Innate ImmunityCell Reports, 2013
- STING is a direct innate immune sensor of cyclic di-GMPNature, 2011
- The Polycomb complex PRC2 and its mark in lifeNature, 2011
- The role of EZH2 and DNA methylation in the silencing of the tumour suppressor RUNX3 in colorectal cancerCarcinogenesis, 2010
- Interferon Alpha Adjuvant Therapy in Patients With High-Risk Melanoma: A Systematic Review and Meta-analysisJNCI: Journal of the National Cancer Institute, 2010
- Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell RecruitmentCancer Research, 2009
- STING is an endoplasmic reticulum adaptor that facilitates innate immune signallingNature, 2008
- EZH2 Expression Is Associated With High Proliferation Rate and Aggressive Tumor Subgroups in Cutaneous Melanoma and Cancers of the Endometrium, Prostate, and BreastJournal of Clinical Oncology, 2006
- The Human Genome Browser at UCSCGenome Research, 2002
- Innate Immune RecognitionAnnual Review of Immunology, 2002